Latest 10-K annual reports

Meridian Corporation announced a significant increase in net income and asset growth for the fiscal year ended December 31, 2025, driven by higher net interest income and strategic loan portfolio expansion.

FS Credit Real Estate Income Trust, Inc. reports a decrease in net income for 2025 amidst market volatility, while maintaining a diversified loan portfolio and active capital management.

BestGofer Inc. reports a net loss for fiscal year 2025, a significant funding shortfall, and delays in its core delivery platform launch, despite acquiring a revenue-generating home inspection subsidiary.

XBiotech Inc. reported a net loss of $45.5 million for fiscal year 2025, driven by increased R&D expenses and executive severance, while highlighting positive oncology clinical trial results and ongoing regulatory discussions for Natrunix.

Stagwell Inc. announced robust financial results for fiscal year 2025, showcasing significant revenue growth, improved profitability, and strategic expansion in digital and AI-powered marketing services.

New England Realty Associates Limited Partnership reported a significant 61.5% decrease in net income for 2025, despite revenue growth, driven by higher operating expenses and interest costs.

USCB Financial Holdings reports increased net income and loan growth in 2025, alongside a strategic securities portfolio restructuring and a subordinated debt issuance.

NorthEast Community Bancorp reported a 5.65% decrease in net income to $44.4 million for 2025, driven by lower net interest income and higher non-interest expenses, despite strong asset quality and a significant reduction in non-performing assets.

Ohio Valley Banc Corp. announced a significant increase in net income and earnings per share for fiscal year 2025, driven by robust loan growth and improved net interest margin.

Alliance Laundry Holdings Inc. announced a 13% increase in net revenues to $1.71 billion and a 14% rise in Adjusted EBITDA to $436.5 million for 2025, alongside a significant debt reduction following its October 2025 IPO.

Bimini Capital Management, Inc. reported a significant return to profitability in 2025 and announced a strategic acquisition of Tom Johnson Investment Management, LLC, signaling a pivot towards a diversified asset management model.

CB Financial Services, Inc. reported a significant decrease in net income for 2025, primarily driven by a pre-tax loss from a strategic investment securities repositioning, despite growth in net interest income and loans.

Trinseo PLC reported a significant net loss of $545.6 million for 2025, received a NYSE delisting notice, and raised substantial doubt about its ability to continue as a going concern, while actively discussing debt restructuring.

Chemung Financial Corporation's 2025 annual report reveals a strategic balance sheet repositioning, including significant securities sales and subordinated debt issuance, impacting net income while strengthening capital and loan growth.

MainStreet Bancshares, Inc. reported a significant return to profitability in 2025, driven by improved net interest income and a recovery in credit loss provisions, despite an increase in non-performing assets.

Colony Bankcorp, Inc. reported significant growth in 2025, fueled by strategic acquisitions and improved net interest income, despite an increase in nonperforming assets.

Copper Property CTL Pass Through Trust reported a significant drop in net income for 2025, driven by a terminated $947 million property sale agreement and increased impairment charges, alongside ongoing litigation.

Norwood Financial Corp reversed its prior year loss with a significant net income of $27.76 million in 2025, driven by increased net interest income and strategic portfolio repositioning.

Talkspace, a virtual behavioral healthcare provider, announced a definitive merger agreement with Universal Health Services, Inc. for $5.25 per share in cash, while reporting significant revenue growth driven by its Payor segment.

Forrester Research, Inc. reported a significant net loss of $119.4 million in 2025, driven by substantial goodwill impairment and declining revenues across all segments.

John Marshall Bancorp, Inc. announced a 24% increase in net income for 2025, driven by improved net interest margin and loan portfolio growth, despite increased provision for credit losses.

Harvard Bioscience, Inc. reported a significant net loss in 2025, driven by goodwill impairment and declining revenues, while initiating a major manufacturing consolidation and debt refinancing.

Barinthus Biotherapeutics plc announced a definitive all-stock merger agreement with Clywedog Therapeutics, Inc., refocusing its pipeline on immunology and inflammation while reporting increased net losses and a Nasdaq listing deficiency.

Savara Inc. announced its Biologics License Application for MOLBREEVI in autoimmune PAP was formally filed by the FDA and granted Priority Review in February 2026, following a resubmission in December 2025 after an initial Refusal to File letter.

Kestrel Group Ltd reported a significant net income for 2025, primarily driven by a bargain purchase gain from its combination with Maiden Holdings, Ltd., despite an underlying operating loss.

U.S. Energy Corp. reported a net loss of $14.4 million for 2025, driven by declining oil and gas production and prices, as it strategically pivots towards industrial gas development in Montana.

Shimmick Corporation significantly reduced its net loss and achieved positive gross margin in fiscal year 2025, driven by strategic project shifts, but disclosed material weaknesses in internal controls and a multi-billion dollar lawsuit.

ChoiceOne Financial Services, Inc. reported a significant increase in total assets and net interest income for 2025, primarily driven by the Fentura Financial merger, despite a decrease in diluted earnings per share.

Emerald Holding, a leading B2B event organizer, reported a 16.2% revenue increase to $463.4 million in 2025, driven by strategic acquisitions and organic growth, despite a net loss of $30.7 million.

Tonix Pharmaceuticals launched its first internally developed FDA-approved product, TONMYA for fibromyalgia, in November 2025, amidst ongoing operating losses and a going concern warning.